WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension: A NICE medical technology guidance

Applied Health Economics and Health Policy

Volumn 12, Issue 3, 2014, Pages 255-265

  Willits, Iain ^a   Keltie, Kim ^a   Craig, Joyce ^b   Sims, Andrew ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT THERAPY; BLOOD PRESSURE MONITOR; CEREBROVASCULAR ACCIDENT; ELECTROCARDIOGRAM; EXTERNAL VALIDITY; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HOME MONITORING; HUMAN; HYPERTENSION; MEDICAL TECHNOLOGY; PRACTICE GUIDELINE; REVIEW; ATRIAL FIBRILLATION; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD PRESSURE MONITORING; COST CONTROL; DEVICES; ECONOMICS; ELECTROCARDIOGRAPHY; PATHOPHYSIOLOGY; PROBABILITY; STATISTICAL MODEL; STROKE; UNITED KINGDOM;

ANTICOAGULANT AGENT;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD PRESSURE MONITORING, AMBULATORY; COST SAVINGS; ELECTROCARDIOGRAPHY; GREAT BRITAIN; HUMANS; HYPERTENSION; MARKOV CHAINS; MODELS, ECONOMIC; STROKE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84901671757     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-014-0096-7     Document Type: Review

References (46)

1. Campbell B, Campbell M. NICE Medical Technologies Guidance: a novel and rigorous methodology to address a new health technology assessment challenge. Appl Health Econ Health Policy. 2012;10(5):295-7.
2. National Institute for Health and Care Excellence. Medical Technologies Evaluation Programme: Process Guide. 2011. http://www.nice.org.uk/media/3A6/14/ MedicalTechnologiesEvaluationProgrammeProcessGuideMarch2012.pdf. Last Accessed March 2014.
3. National Institute for Health and Care Excellence. Medical Technology Guidance 13: WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension. 2013. http://www.nice.org.uk/ nicemedia/live/14020/62321/62321.pdf. Last Accessed March 2014.
4. White J, Carolan-Rees G. PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites. Appl Health Econ Health Policy. 2012;10(5):299-308.
5. Withers K, Carolan-Rees G, Dale M. Pipeline™ embolization device for the treatment of complex intracranial aneurysms. Appl Health Econ Health Policy. 2013;11(1):5-13.
6. National Institute for Health and Care Excellence. Medical Technology Guidance 145. 2011. http://guidance.nice.org.uk/MT/145. Last Accessed March 2014.
7. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypterten. 2013;31:1281-357.
8. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13. (Pubitemid 35472129)
9. Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol. 2003;91(suppl):9G-14G. (Pubitemid 36638516)
10. National Institute for Health and Care Excellence. Clinical Guideline 127: hypertension: clinical management of primary hypertension in adults. 2011. http://www.nice.org.uk/nicemedia/live/13561/56008/56008.pdf. Last Accessed March 2014.
11. Lévy S, Camm AJ, Saksena S, et al. International consensus on nomenclature and classification of atrial fibrillation: a collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace. 2003;5:119-22. (Pubitemid 36372367)
12. National Institute for Health and Care Excellence. Clinical Guideline 36: atrial fibrillation, National clinical guideline for management in primary and secondary care. 2006. http://www.nice.org.uk/nicemedia/live/10982/30055/30055. pdf. Last Accessed March 2014.
13. Benjamin EJ, Chen P, Bild DE, et al. Prevention of atrial fibrillation: Report from an NHLBI workshop. Circulation. 2009;119(4):606-18.
14. Quality and Outcomes Framework (QOF) database. 2012. http://www. gpcontract.co.uk/browse/UK/Atrial%20Fibrillation/12. Last Accessed March 2014.
15. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N. (Pubitemid 28507114)
16. Hobbs FDR, Fitzmaurice DA, Jowett S et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess. 2005; 9(40):1-90.
17. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-8.
18. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death the Framingham Heart Study. Circulation. 1998;98:946-52. (Pubitemid 28446646)
19. Cooke G, Doust J, Sanders S. Is pulse palpation helpful in detecting atrial fibrillation? A systematic review. J Fam Pract. 2006;55(2):130-4. (Pubitemid 43254557)
20. Public Health England. NHS health check: our approach to the evidence. https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/ 224537/NHS-Health-Check-our-approach-to-the-evidence-v2.pdf. Last Accessed March 2014.
21. Stergiou GS, Giovas PP, Gkinos CP, Patouras JD. Validation of the Microlife WatchBP Home device for self home blood pressure measurement according to the International Protocol. Blood Press Monit. 2007;12:185-8. (Pubitemid 46743723)
22. Wiesel J, Wiesel D, Suri R, Messineo FC. The use of a modified sphygmomanometer to detect atrial fibrillation in outpatients. Pace. 2004;27:1-6.
23. Wiesel J, Wiesel DJ, Messineo FC. Home monitoring with a modified automatic sphygmomanometer to detect recurrent atrial fibrillation. J Stroke Cerebrovas Dis. 2007;16(1):8-13. (Pubitemid 46073784)
24. Stergiou GS, Karpettas N, Protogerou A, Nasothimiou EG, Kyriakidis M. Diagnostic accuracy of a home blood pressure monitor to detect atrial fibrillation. J Human Hypertens. 2009;23: 654-8.
25. Wiesel J, Fitzig L, Herschman Y, Messineo FC. Detection of atrial fibrillation using a modified microlife blood pressure monitor. Am J Hypertens. 2009;22(8):848-52.
26. Wiesel J, Abraham S, Messineo FC. Screening for asymptomatic atrial fibrillation while monitoring the blood pressure at home: trial of regular versus irregular pulse for prevention of stroke (TRIPPS 2.0). Am J Cardiol. 2013;111(11):1598-601.
27. Stergiou GS, Jaenecke B, Giovas PP, Chang A, Chung-Yueh Y, Tan TM. A tool for reliable self-home blood pressure monitoring designed according to the European Society of Hypertension recommendations: the Microlife WatchBP Home monitor. Blood Press Monit. 2007;12(2):127-31. (Pubitemid 46412120)
28. Chung Y, de Greeff A, Shennan A. Validation and compliance of a home monitoring device in pregnancy: microlife WatchBP home. Hypertens Pregnancy. 2009;28(3):348-59.
29. Wessel S, van der Hoeven NV, van den Born BJH, Cammenga M, van Montfrans GA. Microlife WatchBP for home blood pressure measurement more accurate in 'diagnostic' mode compared to usual mode. J Hypertens. 2010;28 (e-supplement):e454.
30. Kearley K, Selwood MP, Van den Bruel A et al. What is the best way to screen for atrial fibrillation in primary care? A comparison of the accuracy of 3 methods: nurse pulse palpation, a hand-held ECG and a modified BP monitor. 2010. http://www.in2health.org/wp-content/uploads/2013/09/What-is-the-best-way- to-screen-for-atrial-fibrillation-in-primary-care.pdf. Last Accessed March 2014.
31. Worster A, Carpenter C. Incorporation bias in studies of diagnostic tests: how to avoid being biased about bias. CJEM. 2008;10(2):174-5.
32. Critical Appraisal Skills Programme (CASP). http://www.caspuk.net/. Last Accessed March 2014.
33. Kelly S, Berry E, Roderick P. The identification of bias in studies of the diagnostic performance of imaging modalities. Br J Radiol. 1997;70:1028-35. (Pubitemid 27464204)
34. Altman DG, Bland JM. Diagnostic test 2: predictive values. BMJ. 1994;309(9):102.
35. Mauskopf JA, Paul JE, Grant DM, Stergachis A. The role of cost-consequence analysis in healthcare decision-making. PharmacoEconomics. 1998;13(3):277-88. (Pubitemid 28123367)
36. Morgan S, Mant D. Randomised trial of two approaches to screening for atrial fibrillation in UK general practice. Br J Gen Pract. 2002;52:373-80.
37. National Institute for Health and Care Excellence. Atrial fibrillation: the management of atrial fibrillation. Costing report. 2006. http://www.nice.org.uk/nicemedia/live/10982/30061/30061.pdf. Last Accessed March 2014.
38. Saka O, McGuire A, Wolfe C. Cost of stroke in the United Kingdom. Age Ageing. 2009;38:27-32.
39. National Institute for Health and Care Excellence. Medical Technologies Evaluation Programme: methods guide. 2011. http://www.nice.org.uk/media/3A6/09/ MedicalTechnologiesEvaluationProgrammeMethodsGuideMarch2012.pdf. Last Accessed March 2014.
40. Lip GYH, Tello-Montoliu A. Management of atrial fibrillation. Heart. 2006;92:1177-82. (Pubitemid 44125256)
41. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. New York: Oxford University Press; 2005.
42. Manning WG, Fryback DG, Weinstein MC. Refecting uncertainty in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russel LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University; 1996. p. 247-75.
43. Cooper NJ, Sutton AJ, Abrams KR. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section. Stat Methods Med Res. 2002;11(6):491-512. (Pubitemid 36096867)
44. Fitzmaurice DA, Hobbs FD, Jowett S, Mant J, Murray ET, Holder R, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ. 2007;335(7616):383.
45. Department of Health. 2009-10 reference costs publication. 2010. https://www.gov.uk/government/publications/nhs-reference-costs-2009-2010. Last Accessed March 2014.
46. National Institute of Health and Care Excellence. NICE Technology appraisal guidance 249, 2012. Atrial fibrillation - dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. http://guidance.nice.org.uk/TA249/Guidance/pdf/English. Last Accessed March 2014.